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Basal-like tumours account for 15% of invasive breast carcinomas and are associated with a poorer prognosis and resistance to
therapy. We hypothesised that this aggressive phenotype is because of an intrinsically elevated hypoxic response. Microarrayed
tumours from 188 patients were stained for hypoxia-inducible factor (HIF)-1a, prolyl hydroxylase (PHD)1, PHD2, PHD3 and factor
inhibiting HIF (FIH)-1, and carbonic anhydrase (CA) IX stained in 456 breast tumours. Tumour subtypes were correlated with
standard clincopathological parameters as well as hypoxic markers. Out of 456 tumours 62 (14%) tumours were basal-like. These
tumours were positively correlated with high tumour grade (Po0.001) and were associated with a significantly worse disease-free
survival compared with luminal tumours (Po0.001). Fifty percent of basal-like tumours expressed HIF-1a, and more than half
expressed at least one of the PHD enzymes and FIH-1. Basal-like tumours were nine times more likely to be associated with CAIX
expression (Po0.001) in a multivariate analysis. Carbonic anhydrase IX expression was positively correlated with tumour size
(P¼0.005), tumour grade (Po0.001) and oestrogen receptor (ER) negativity (Po0.001). Patients with any CAIX-positive breast
tumour phenotype and in the basal tumour group had a significantly worse prognosis than CAIX-negative tumours when treated with
chemotherapy (Po0.001 and P¼0.03, respectively). The association between basal phenotype and CAIX suggests that the more
aggressive behaviour of these tumours is partly due to an enhanced hypoxic response. Further, the association with chemoresistance
in CAIX-positive breast tumours and basal-like tumours in particular raises the possibility that targeted therapy against HIF pathway or
downstream genes such as CAs may be an approach to investigate for these patients.
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Current prognostic and predictive markers of invasive breast
cancer rely largely on histological indicators such as tumour size,
grade, nodal status and receptor status, which define broad patient
groups for different treatment regimens. However, it is recognised
that there are many patients within such groups who are
overtreated or undertreated with conventional therapies, strongly
suggesting that current stratification does not fully account for the
molecular heterogeneity and diverse biological behaviour of breast
cancer. Recently cDNA microarray studies have classified breast
cancers broadly into five subtypes, based on their different
expression profiles: normal breast-like, luminal A (oestrogen
receptor (ER) positive), luminal B (ER positive and proliferative),
HER2 overexpressing and basal (Sorlie et al, 2001, 2003), the latter
having a particularly poor clinical outcome (Sorlie et al, 2003; Abd
El-Rehim et al, 2004; Nielsen et al, 2004).
Basal-like breast cancers derive their name from their charac-
teristic expression of basal and myoepithelial markers such as
cytokeratins (CK) 5, 14 and 17 (Jarasch et al, 1988; Wetzels et al,
1991). These tumours account for up to 15% of all invasive breast
cancers (van de Rijn et al, 2002; Abd El-Rehim et al, 2004; Nielsen
et al, 2004; Matos et al, 2005). Basal-like tumours are more
frequently observed in patients with BRCA1-related cancers
(Foulkes et al, 2004). In contrast to the normal breast-like and
luminal subtypes, basal-like breast cancers have a particularly
aggressive phenotype, being more likely to be high-grade, ER
negative (Malzahn et al, 1998; Korsching et al, 2002; Nielsen et al,
2004), and are associated with a higher proliferative index
(Korsching et al, 2002; Matos et al, 2005). Expression of basal
CKs is also associated with loco-regional recurrence, distant
metastasis and a poor overall survival in node-positive and node-
negative patients (Malzahn et al, 1998; van de Rijn et al, 2002). In
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saddition, basal-like tumours differ from normal breast-like and
luminal tumours in their response to chemotherapy. Although
basal-like tumours do not respond well to anthracycline-based
therapy (Banerjee et al, 2006), they show an impressive
pathological response to paclitaxel followed by a combination of
5-fluorouracil, doxorubicin and cyclophosphamide (Rouzier et al,
2005). They also have a BRCA1 phenotype and therefore are
sensitive to platinum-based therapies (Kennedy et al, 2004).
In addition to being mostly high-grade tumours, a so-called
triple negative phenotype (ER, progesterone receptor (PR) and
HER2 negative), basal-type breast cancers may also have a
characteristic central acellular or necrotic zone (Tsuda et al,
1999; Fulford et al, 2006). Tumour necrosis is a consequence of
hypoxia. Hypoxia is a predictor of poor disease-free and overall
survival in breast cancer (Fisher et al, 1993; Hockel and Vaupel,
2001), and is associated with resistance to radiation and certain
chemotherapeutic regimes (Teicher et al, 1990). As the hypoxia-
inducible factor (HIF) pathway has been shown to be pivotal in the
hypoxic tumour response and to mediate many of the above
adverse effects, and in view of the link between basal-like breast
cancer, hypoxia and an aggressive phenotype, we have examined
the HIF pathway, including the expression of HIF-1a, its regulatory
enzymes the prolyl hydroxylase domain enzymes PHD-1, PHD-2,
PHD-3, factor inhibiting HIF-1 (FIH-1) and carbonic anhydrase
(CA) IX, a downstream target of HIF-1a in a series of
breast cancers, and compared the expression of each marker
by correlating it with various standard clinicopathological
parameters.
MATERIALS AND METHODS
Patient characteristics
Tumour tissue microarray cores (1mm cores) were collected from
621 invasive breast carcinomas collected from patients who had
undergone surgery at the John Radcliffe Hospital, Oxford, UK and
from the Garvan Institute, Sydney, Australia. This study has
Ethical Committee approvals (number JR C02.216 and HREC SVH
H94/080, HREC SVH 06336 H00036). All patients had operable
breast carcinomas and were not diagnosed with metastatic disease
at the time of presentation. Information regarding patient
characteristics, including age, tumour size, grade, histology, nodal
status, ER and HER2 status, were collected from the clinical and
pathological records. The median age of patients included in this
study was 55 years (range 24–87 years). Eighty-eight percent of
tumours were invasive ductal of no specific type, 3% were invasive
lobular carcinoma and 3% were of other histological classifications
(data was unavailable for the remaining 6%). Median tumour size
was 20mm and the median tumour grade was two. Forty-four
percent of patients had nodal disease. Sixty-eight percent of
tumours were ER positive and 16% were HER2 positive. Patients
less than 50 years of age with node-positive, ER-negative tumours
or tumours larger than 3cm received adjuvant chemotherapy
(cyclophosphamide, methotrexate and 5-fluorouracil (CMF) or
adriamycin and cyclophosphamide (AC). Patients with hormone-
responsive tumours who were more than 50 years of age received 5
years of endocrine therapy. Patients were followed up for a median
period of 131.9 months. During this time, 137 patients developed
recurrence (30.0%) and 99 deaths (21.7%) were considered as
breast-cancer related.
Immunohistochemistry
Formalin-fixed paraffin-embedded tissue sections were stained for
the various hypoxic markers (Supplementary Table 1). Substitu-
tion of the primary antibody with phosphate-buffered saline
served as a negative control. Transfected COS-1 cells expressing
PHD1, PHD2, PHD3, FIH-1 and HIF-1a were used as positive
controls. In each run a tumour is known to be positive for CAIX
was included.
Scoring was carried out by two observers simultaneously. ER,
HER2, EGFR and CK5/6 staining was used to classify tumours into
four subgroups as per Neilson et al. basal group (ER negative,
HER2 negative, CK5/6 and/or EGFR positive), luminal group (ER
positive, HER2 negative), HER2 group (HER2 positive) and a
negative group (ER negative, HER2 negative, CK5/6 negative and
EGFR negative) (Nielsen et al, 2004). Tumours with any nuclear
staining for HIF-1a were considered positive in the analysis. The
levels of staining for PHD1, PHD2 and PHD3 were scored with
respect to the percentage of cells and the intensity of staining in
the cytoplasm. The scoring system for intensity was: 0¼no
staining, 1¼weak staining, 2¼moderate staining, 3¼strong
staining; and the scoring system for percentage was: 0¼no cells
staining positive, 1¼p10% cells staining positive, 2¼11–50%
positive cells, 3¼51–80% positive cells, 4¼X80% positive cells.
Tumours with a cytoplasmic intensity score of X2 and a
percentage score of X1 were considered positive for PHD1,
PHD2 and PHD3 in the analysis, in accordance with their site of
action. Only tumours showing a strong membranous staining in
X10% or more cells were considered positive for CAIX (Tan et al,
2007). Tumours with a nuclear intensity score of X2 and a
percentage score of X1 were considered positive for FIH-1 in the
analysis (Tan et al, 2007). Owing to loss of tumour cores, only 456
out of 621 patients with full phenotype of ER, HER2, EGFR and
CK5/6, which are required to classify tumours were available.
Similarly, HIF-1a and the PHDs were available in only 188 out of
456 tumours.
Statistical methods
Correlations were evaluated using either the one-way ANOVA or
w
2 test where appropriate. Kaplan–Meier survival curves were
calculated using tumour recurrence (defined as the first re-
appearance of tumour at any site after definitive treatment) and
cancer-related death as the endpoints and compared using a log-
rank test. Binary logistic regression was used for multivariate
analyses and the Cox proportional hazard regression model was
used to identify independent prognostic factors for disease-free
and overall survival. The analyses were carried out with SPSS 16.0
(SPSS Inc., 233 South Wacker Drive, IL, USA). A two-tailed P-value
test was used in all analyses and a P-value of o0.05 was considered
statistically significant.
RESULTS
Expression of ER, HER2, CK5/6 and EGFR in invasive
breast cancer
Out of 456 tumours 310 (68%) were ER positive; of these, 289
tumours were also HER2 negative and were therefore considered to
be of the luminal group (Table 1). Seventy-five tumours (16%)
were HER2 positive, regardless of their ER, CK5/6 and EGFR
status, and were considered to be of the HER2 group. Of the 169
ER-negative tumours, 62 (14%) were also HER2 negative but
CK5/6 and/or EGFR positive; these were considered to be of the
basal-like group. Thirty tumours were negative for ER, HER2, CK5/
6 and EGFR and were considered to be of the negative group
(Table 1) (Supplementary material Figure 1).
Expression of HIF-1a and its regulatory enzymes PHD1,
PHD2, PHD3 and FIH
Ninety-four out of 188 tumours (50%) stained positive for HIF-1a
(Table 1) (Supplementary material Figure 1). Of these, 64 tumours
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s(68%) were of the luminal group, 13 tumours (14%) were
of the basal group, 12 (13%) were of the HER2 group and 5
(5%) were of the negative group. Although only 8, 10 and 12% of
luminal, basal-like and HER2 tumours, respectively, expressed all
three PHD enzymes, the majority expressed at least one PHD
enzyme (63, 52 and 72, respectively) (Table 1). None of the six
negative tumours expressed all three PHD enzymes although all
expressed at least one PHD enzyme. More than half of all the
tumours expressed FIH-1 (63% of luminal tumours, 52% of basal
tumours, 68% of HER2 tumours and 50% of negative tumours)
(Table 1).
Correlation of CAIX expression in invasive breast
carcinoma with clinicopathological parameters
CAIX was positive in 59 out of 407 tumours (14%) (Table 2). The
majority of these tumours (26 out of 59 (44%)) were of the basal-
like group. Carbonic anhydrase IX expression was significantly
correlated with a larger tumour size (P¼0.005), high tumour
grade (Po0.001) and ER negativity (Po0.001) (Table 2). There
was no correlation with patient age, nodal status or HER2 status
(P40.05) (Table 2). CAIX expression showed no significant
correlation with HIF-1a expression (Table 2).
Correlation of breast tumours stratified by intrinsic
subtype with CAIX, HIF-1a and its regulatory enzymes
Basal-like tumours were 8.9 times more likely to express CAIX
(Po0.001, 95% CI 3.86–20.29) than luminal tumours (Table 3).
This association is significant (o0.001) even after controlling for
the effect of tumour size and grade. There was no significant
correlation between breast tumour subtypes and HIF-1a or its
regulatory enzymes (P40.05).
Correlation of breast tumours stratified by intrinsic
subtype with clinicopathological parameters and survival
outcome
Basal-like tumours were associated with high tumour grade
(Po0.001), but were not correlated with patient age, tumour size
or nodal status (P40.05). Basal-like tumours and HER2 tumours
shared a similar poor disease-free survival outcome (Supplemen-
tary Figure 2) and were associated with a significantly shorter
disease-free survival compared with luminal tumours (Po0.001,
Table 1 Correlation analysis of 456 invasive breast carcinomas with
clinicopathological parameters and CA9
Luminal
(n¼289)
HER2
(n¼75)
Basal
(n¼62)
Negative
(n¼30) P-value
Patient age 0.64
Median (years) 56.0 55.2 54.0 52.7
Tumour size 0.40
Median (mm) 18.0 22.0 22.5 20.5
Tumour grade o0.001
17 1 4 2 4
2 156 16 12 12
35 8 5 4 4 7 1 4
Nodal status 0.75
Negative 162 40 34 17
Positive 125 34 28 13
CAIX o0.001
Negative 242 27 57 22
Positive 14 26 16 3
Nuclear HIF1a 0.53
Negative 54 10 13 1
Positive 64 12 13 5
Cytoplasmic PHD1 0.76
Negative 68 10 15 3
Positive 51 12 11 3
Cytoplasmic PHD2 0.41
Negative 71 9 16 4
Positive 47 11 7 2
Cytoplasmic PHD3 0.87
Negative 70 13 14 3
Positive 43 10 11 3
Nuclear FIH-1 0.51
Negative 45 6 12 3
Positive 80 17 15 3
CAIX¼carbonic anhydrase IX; PHD¼prolyl hydroxylase. no456 because data are
not available.
Table 2 Correlation analysis of CAIX expression and clinicopathological
parameters
CAIX positive
(n¼59)
CAIX negative
(n¼348) P-value
Patient age 0.96
Median (years) 55.0 57.0
Tumour size 0.005
Median (mm) 25.0 19.0
Tumour grade o 0.001
10 9 6
2 19 189
3 56 154
Nodal status 0.168
Negative 34 242
Positive 40 195
ER status o0.001
Negative 54 110
Positive 19 326
HER2 status 0.065
Negative 43 291
Positive 16 57
Nuclear HIF-1a 0.13
Negative 6 54
Positive 15 62
CAIX¼carbonic anhydrase IX; PHD¼prolyl hydroxylase; HIF¼hypoxia-inducible
factor. no456 because data are not available.
Table 3 Multivariate analysis binary logistic regression model of the
effect of CAIX expression on tumour subtype, using luminal tumours as a
baseline (n¼406)
Odds ratio 95% CI P-value
Tumour size 1.00 0.98–1.03 0.79
Grade 2.7 1.45–5.00 0.002
Basal tumours 8.9 3.86–20.29 o0.001
HER2 tumours 2.7 1.16–6.21 0.02
Negative tumours 1.6 0.40–6.09 0.52
CAIX¼carbonic anhydrase IX.
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from the analysis because of the small sample size but are included
the figure).
CAIX expression and survival in breast cancer patients
Patients with tumours expressing CAIX had a significantly worse
disease-free survival (Po0.001) (Figure 1A). There was a
significant difference in survival in patients with any type of
breast carcinoma treated with chemotherapy stratified by CAIX
(Po0.001) (Figure 1B). Patients with CAIX-positive basal-like
breast cancers who were treated with chemotherapy had a
significantly shorter overall survival (P¼0.03) than treated
patients with CAIX-negative basal-like breast cancers
(Figure 1C). In the absence of chemotherapy treatment, there
was no significant difference in overall survival among the
intrinsic subtypes (P¼0.07), or when basal-like carcinomas were
stratified according to CAIX expression (P¼0.27). There was no
significant difference in overall survival in patients not treated
with chemotherapy with any type of breast carcinoma (P¼0.07) or
basal-like carcinoma stratified by CAIX (P¼0.27). In a multi-
variate Cox regression model patients who had tumours that were
CAIX positive and who were treated with chemotherapy had a
significantly shorter overall survival (Po0.001), whereas CAIX had
no effect on survival in patients not treated with chemotherapy
(P¼0.48) (Table 4A and B). To test for treatment interactions,
CAIX, chemotherapy and their interaction variables were entered
into the Cox regression model as a second block. The interaction of
chemotherapy with CAIX was significant in the final model
(P¼0.04) (Table 4C).
DISCUSSION
mRNA expression profile studies have confirmed the long-
standing histological observation that breast cancer is a
heterogeneous disease (Perou et al, 2000; Sorlie et al, 2001,
2003). These studies have broadly classified breast cancers into
four categories: luminal A (strongly ER positive), luminal B (also
ER positive but proliferative), HER2 and basal-like groups.
Although these categories were identified using unsupervised
clustering, the groupings also conferred prognostic information,
with carcinomas of the basal-like group having a shorter survival
than tumours of the luminal group (Sorlie et al, 2001) and being
resistant to anthracycline-based chemotherapy (Banerjee et al,
2006). Expression of the hypoxia-inducible factor-1a is also
associated with a poor prognosis and resistance to chemotherapy
(Teicher et al, 1981; Schindl et al, 2002; Bos et al, 2003), and in
view of the association between basal-like breast cancer, necrosis,
their aggressive behaviour and poor response to chemotherapy we
hypothesised that these tumours may have an intrinsically
enhanced hypoxic response. We therefore examined the hypoxic
pathway in a series of breast cancers.
Although there is no generally recognised definition of the
categories for stratification into intrinsic subgroups (different
studies using various markers such as CK5, CK14, CK17, EGFR,
KIT, p63 and smooth muscle actin (Nagle et al, 1986; Wetzels et al,
1991; Malzahn et al, 1998; Tsuda et al, 1999; van de Rijn et al, 2002;
Abd El-Rehim et al, 2004; Matos et al, 2005; Fulford et al, 2006) to
identify basal-like tumours), in this study we have used the
classification developed by Nielsen et al (2004). This uses a
combination of ER, HER2, CK5 and EGFR to generate four groups,
which in this study gives a frequency of basal-like cancers in this
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Figure 1 (A) Kaplan–Meier disease-free survival curves stratifying patients by CAIX expression (Po0.001) (n¼407). (B) Kaplan–Meier overall survival
curves stratifying all tumours treated with chemotherapy by expression of CAIX (Po0.001) (n¼427). (C) Kaplan–Meier overall survival curves stratifying
patients with basal-like tumours treated with chemotherapy by expression of CAIX (P¼0.03) (n¼26).
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Abd El-Rehim et al, 2004; Nielsen et al, 2004; Matos et al, 2005).
Central to the hypoxic response is the transcription factor HIF.
We have examined the role of the key pathway members regulating
HIF-mediated transcription, including HIF-1a, the PHDs, FIH and
CAIX in a series of breast cancers classified into intrinsic subtypes
as described above (Wykoff et al, 2000). We observed that basal-
like tumours were many times more likely to express CAIX.
Carbonic anhydrase IX is a transmembrane protein involved in
maintaining a low pericellular pH through its reversible conver-
sion of carbon dioxide and water into carbonic acid (Pastorek et al,
1994; Opavsky et al, 1996), and has been shown to maintain
survival of breast tumour cells under hypoxic conditions (Potter
and Harris, 2003). Carbonic anhydrase IX is not present in normal
breast tissues (Bartosova et al, 2002), but is upregulated in invasive
tumours with increasing intensity, with increasing distance from
tumour vessels (Span et al, 2003) tightly under the regulation of
HIF-1a (Grabmaier et al, 2004). Carbonic anhydrase IX expression
has been shown to correlate with the distribution of pimonidazole,
a chemical marker of hypoxia (Opavsky et al, 1996; Wykoff et al,
2000) and with hypoxia measured by Eppendorf microelectrode in
advanced cervical cancer (Loncaster et al, 2001). On the basis of
these data it has been suggested that CAIX immunohistochemistry
is a surrogate marker for detecting hypoxia in tumour samples.
Thus, the association between basal phenotype and CAIX supports
the notion that these tumours have an enhanced hypoxic response
(Wykoff et al, 2000; Lal et al, 2001).
Nevertheless, despite a strong correlation with CAIX, we did not
observe a correlation between basal tumours and HIF-1a or
between CAIX and HIF-1a in this study. This is unlikely to be due
to spatial reasons because TMA are ideal for investigating
relationships between biomarkers as the same area of tumour is
being examined, but is probably due to the difference in half-lives
of HIF-1a and CAIX. Hypoxia-inducible factor-1a is rapidly
degraded within minutes of reoxygenation (Jiang et al, 1996),
whereas CAIX has a half-life of 2–3 days (Turner et al, 2002;
Rafajova et al, 2004). This absence of an association is in
agreement with reports (Tomes et al, 2003; Sobhanifar et al,
2005) of the presence of CAIX without HIF-1a expression in
perinecrotic regions in solid tumours (Sobhanifar et al, 2005).
CAIX expression, like a basal-like phenotype, is associated with an
increased risk of recurrence and poorer overall survival (Chia et al,
2001). In this series, those patients with tumours of either a basal-
like phenotype or expressing CAIX were associated with an adverse
outcome. Nevertheless, in this study and in others reported earlier,
CAIX expression is also positively correlated with high tumour grade
and size (Chia et al, 2001; Span et al, 2003), the former feature also
characteristic of basal tumours. Thus, hypoxic stress may not be part
of the basal intrinsic subtype but might be due to an association with
grade. Although this cannot be completely discounted, our data
show that both basal-like and HER2 cancers are significantly
associated with high tumour grade (as expected) but the basal group
was more likely to be CAIX positive, whereas the HER2 subtype was
less likely to be CAIX positive. Furthermore, in a multivariate
analysis including tumour size and grade, basal-like phenotype was
still associated with CAIX expression. Thus, the data are strongly
suggestive of an enhanced hypoxic drive in this tumour type. This is
further supported by interrogation of expression data sets (Onco-
mine, www.oncomine.org), where there is significant upregulation of
not only HIF-1a and CAIX but also other HIF-1a-regulated genes
such as vascular endothelial growth factor-A, BNIP3 and Glut-1.
Moreover, patients with basal-like tumours who have not received
chemotherapy have a similar prognosis irrespective of CAIX
expression, whereas patients with basal-like tumours that are CAIX
positive and who have received chemotherapy have a significantly
shorter overall survival than patients with basal-like tumours that are
CAIX negative. This suggests that CAIX-positive basal-like tumours
are particularly resistant to chemotherapy, in contrast to CAIX-
negative basal-like tumours, which are able to respond to
chemotherapy. A potential mechanism for this action is through
trapping of chemotherapeutic agents outside the cell when the
extracellular environment is acidic (Mahoney et al, 2003).
The resistance effect of CAIX/hypoxia seems to hold irrespective
of tumour subtype as, unlike patients not treated with chemo-
therapy, treated patients with any tumour phenotype positive for
CAIX also had a significantly worse survival than patients with
tumours negative for CAIX in the multivariate analyses. This is in
keeping with our studies in the neoadjuvant context, in which
CAIX was associated with a shorter relapse-free survival in patients
treated with CMF (Generali et al, 2006a, b), and in patients treated
in the adjuvant setting, in which CAIX measured by RT–PCR was
associated with chemoresistance (Span et al, 2003). Thus, these
data suggest that CAIX is predictive rather than prognostic.
Molecular genetic studies of basal-like breast carcinomas have
shown that tumours with a basal-like phenotype have a higher
number of unbalanced chromosomal changes and rate of loss of
heterozygosity than luminal-type breast tumours (Korsching et al,
2002; Jones et al, 2004). In addition, basal-like tumours are a
distinctive feature of BRCA1-associated breast cancers. Although
BRCA1 is involved in a large number of cellular processes, it is the
maintenance of genomic stability that has been proposed to be
the principal factor underlying cancer predisposition in mutation
carriers (Baldeyron et al, 2002). Thus, it is also of interest that
hypoxia is recognised to induce genomic instability (Cheng and
Loeb, 1993; Sutherland, 1998; Semenza, 2000; Chan et al, 2008),
Table 4A Cox regression model, overall survival, all breast cancers
treated with chemotherapy (n¼182)
Odds ratio 95% CI P-value
Nodal status 1.77 0.62–5.05 0.29
Grade 2.38 1.36–4.164 0.002
CAIX 3.20 1.79–5.701 o0.001
Size 1.04 1.02–1.058 o0.001
CAIX¼carbonic anhydrase IX
Table 4B Cox regression model, overall survival, all breast cancers
treated with chemotherapy (n¼262)
Odds ratio 95% CI P-value
Nodal status 2.27 1.04–4.96 0.04
Grade 1.90 1.12–3.25 0.02
CAIX 1.33 0.60–2.95 0.48
Size 1.04 1.02–1.06 o0.001
CAIX¼carbonic anhydrase IX
Table 4C Cox regression model, overall survival, all breast cancers with
CAIX and chemotherapy as interaction variables (n¼441)
Odds ratio 95% CI P-value
Grade 1.98 1.34–2.92 0.001
Age 1.00 0.99–1.02 0.65
Size 1.04 1.03–1.05 o0.001
Oestrogen receptor 0.74 0.46–1.20 0.22
Nodal status 2.22 1.15–4.26 0.02
Additions to model
CAIX 1.09 0.49–2.42 0.83
Chemotherapy 0.75 0.38–1.49 0.41
CAIX chemotherapy 2.65 1.03–6.82 0.04
CAIX¼carbonic anhydrase IX.
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sand it is interesting to speculate whether the genomic alterations
observed in basal-like breast carcinomas may partly be the result
of the enhanced hypoxic response in this subtype. Nevertheless,
these genomic studies have been carried out on a small number of
tumours (Jones et al, 2001, 2004) and additional data are required
to support this thesis.
In summary, the more aggressive phenotype seen in basal-like
tumours may be at least partly due to the intrinsically enhanced
hypoxic properties of basal-like breast cancers. It suggests that as
this tumour type is particularly difficult to treat, because they are
both hormonal non-responsive and resistant to chemotherapy,
targeting HIF with small molecule inhibitors, HRE-regulated
gene therapies, carbonic anhydrase inhibitors or the use of
bio-reductive drugs may be of particular use in treating this
aggressive cancer (Supuran, 2008).
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